1. Home
  2. About NIDDK
  3. Staff Directory
  4. Ellen Leschek, M.D.

Ellen Leschek, M.D.

Type 1 and type 2 diabetes clinical research; inborn errors of metabolism

Responsibilities & Activities

As program director for Type 1 Diabetes TrialNet, I oversee a large international clinical trial network that performs studies addressing the prevention of and early intervention in type 1 diabetes, as well as the natural history of this disease. I also serve as the executive secretary for the TrialNet Data and Safety Monitoring Board as well as the TrialNet External Evaluation Committee. As program director for the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study, I oversee the administrative aspects of the DCCT/EDIC Coordinating Center and the DCCT/EDIC Administrative Core and serve as the executive secretary for the DCCT/EDIC Observational Study Monitoring Board and the DCCT/EDIC External Evaluation Committee. I am the project scientist for the Restoring Insulin Secretion (RISE) Consortium, a multi-center network of investigators testing interventions designed to preserve or improve β-cell function in prediabetes or early type 2 diabetes. In this capacity, I assist the Steering Committee in carrying out the studies and provide scientific support to the study group, including protocol development, quality control, interim data monitoring, final data analysis, preparation of publications and overall performance monitoring. As program director for the Rare and Atypical DIAbetes NeTwork (RADIANT), I oversee a large network of clinical sites that identify and study individuals with atypical forms of diabetes to better inform the study of type 2 diabetes. I also serve as the executive secretary for the RADIANT Observational Study Monitoring Board.

My responsibilities also include membership on the NIH Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt-Jakob Disease. In this capacity, I review all deaths occurring in members of the cohort treated with cadaverine hGH through the National Hormone Pituitary Program. I serve as a member of the NIDDK Clinical Studies Working Group and of the Division of Diabetes, Endocrinology, and Metabolic Diseases Clinical Working Group. I am also a member of the Division of Diabetes, Endocrinology and Metabolic Diseases Clinical Trial Oversight Committee. In addition, I am a special volunteer for the Pediatric Endocrinology Clinic where I evaluate and treat pediatric endocrinology patients and train NICHD’s pediatric endocrinology fellows.

Research Programs

Clinical Research in Type 1 Diabetes
Determinants, etiology, progression, prevention, and treatment of type 1 diabetes in children and adults.

Diabetes, Endocrine, & Metabolic Disease Translational Research
Studies that translate scientific findings into practice to enhance human health of those with, or at risk for, metabolic disease.

Committees & Working Groups

  • NIH Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt-Jakob Disease, Member
  • NIDDK Clinical Studies Working Group, Member
  • DEM Clinical Studies Working Group, Member
  • Trans-NIH Biomarkers in Pediatric Therapeutics Special Interest Group, Diabetes Working Group Chair
  • DEM Clinical Trial Oversight Committee, Member